

# Michal Sarnecki

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/973830/publications.pdf>

Version: 2024-02-01

9  
papers

144  
citations

1478505

6  
h-index

1588992

8  
g-index

10  
all docs

10  
docs citations

10  
times ranked

341  
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption. <i>Nature Medicine</i> , 2020, 26, 498-501.	30.7	43
2	First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector. <i>Journal of Infectious Diseases</i> , 2018, 218, 633-644.	4.0	35
3	Immunogenicity and estimation of antibody persistence following vaccination with an inactivated virosomal hepatitis A vaccine in adults: A 20-year follow-up study. <i>Vaccine</i> , 2017, 35, 1448-1454.	3.8	26
4	Long-term Antibody Persistence in Children After Vaccination With the Pediatric Formulation of an Aluminum-free Virosomal Hepatitis A Vaccine. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, e85-e91.	2.0	13
5	Long-term Serologic Follow-up of Children Vaccinated with a Pediatric Formulation of Virosomal Hepatitis A Vaccine Administered With Routine Childhood Vaccines at 12-15 Months of Age. <i>Pediatric Infectious Disease Journal</i> , 2016, 35, e220-e228.	2.0	11
6	Immunogenicity and safety of a pediatric dose of a virosomal hepatitis A vaccine in healthy children in India. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 2089-2097.	3.3	10
7	The Safety and Immunogenicity of Two Hepatitis B Vaccine Formulations (Thiomersal-free and) Tj ETQq1 1 0.784314 rgBT /Overlock 1079-83.	2.0	2
8	Comparative Efficacy, Safety and Immunogenicity of Hepavax-Gene TF and Engerix-B Recombinant Hepatitis B Vaccines in Neonates in China. <i>Pediatric Infectious Disease Journal</i> , 2017, 36, 94-101.	2.0	2
9	Development and performance characteristics of novel code-based algorithms to identify invasive <i>Escherichia coli</i> disease. <i>Pharmacoepidemiology and Drug Safety</i> , 0, , .	1.9	2